摘要
Introduction / background
To compare the short-term clinical outcomes of erenumab, galcanezumab, and rimegepant in patients with chronic migraine, focusing on headache burden, pain severity, and pericranial tenderness.
Methods
This real-world longitudinal study included 95 patients receiving erenumab (n=40), galcanezumab (n=19), or rimegepant (n=36), with assessments at baseline and months 1–3. Outcomes included monthly headache days (MHD), attack frequency, visual analog scale (VAS) scores, responder rates, and pericranial tenderness. Overlap weighting, longitudinal regression models, and exact tests were used for statistical analyses.
Results
All three treatments were associated with improvements in headache outcomes. Overlap-weighted mean MHD decreased from 25.04 to 11.75, 24.96 to 7.32, and 23.82 to 9.20 days/month, respectively, by month 3, without significant between-group differences (all P>0.05). Month 3 ≥50% MHD responder rates were 72.41%, 73.33%, and 73.53%, respectively. Adjusted VAS scores differed between treatments (P<0.001), with lower scores in the galcanezumab group, although the treatment-by-time interaction was not significant (P=0.306). Pericranial tenderness positivity decreased from 80.00%, 57.89%, and 69.44% at baseline to 44.83%, 20.00%, and 44.12% at month 3, respectively. No significant difference in headache response was observed between pooled CGRP monoclonal antibodies and rimegepant among patients with baseline tenderness.
Conclusions
All three CGRP-targeted therapies were associated with reduced headache burden and pain severity, accompanied by declining pericranial tenderness positivity. Galcanezumab showed lower adjusted VAS scores, but comparative findings require cautious interpretation. Pericranial tenderness warrants further investigation as a complementary clinical outcome.
